Perioperative use of Antifibrotic Medications Associated with Lower Rate of Manipulation after Primary TKA; An Analysis of 101,366 Patients.
Academic Article
Overview
abstract
INTRODUCTION: Several commonly prescribed medications have known antifibrotic properties and have been shown to reduce postoperative scar formation in other clinical areas, but it is unknown whether use of such medications perioperatively in patients undergoing TKA may improve rates of postoperative stiffness. METHODS: A large US employer-sponsored healthcare database (Truven Marketscan) was queried for patients who underwent elective primary TKA for primary osteoarthritis between 2015-2019. Demographic information and comorbidities were recorded along with whether patients were prescribed one of several medications with known antifibrotic properties during the three months before or after surgery. RESULTS: Complete data was available for 101,366 patients undergoing TKA, of which 4,536 underwent MUA (4.5%). Perioperative use of any antifibrotic medication was associated with a lower likelihood of undergoing MUA (p<0.001). When controlling for age, sex, comorbidities, opioid use, length of stay, among other variables, perioperative use of specific ACE inhibitors (OR 0.91, CI 0.84-1, p=0.042), COX-2 inhibitors (OR 0.88, CI 0.81-0.96, p=0.002), and angiotensin II receptor blockers, specifically losartan (OR 0.80, CI 0.70-0.91, p=0.007) all remained significantly associated with lower rates of MUA. CONCLUSION: This study, spanning over a hundred thousand primary TKA procedures over a recent five-year period, demonstrates an association between perioperative use of specific medications with antifibrotic properties and a decreased rate of MUA. These data will help inform future studies aimed to prospectively evaluate the potential of antifibrotic medications in preventing postoperative stiffness in high-risk patients undergoing knee arthroplasty.
